PL4426270T3 - Nanocząsteczki lipidowe do dostarczania oligonukleotydów - Google Patents

Nanocząsteczki lipidowe do dostarczania oligonukleotydów

Info

Publication number
PL4426270T3
PL4426270T3 PL22813505.9T PL22813505T PL4426270T3 PL 4426270 T3 PL4426270 T3 PL 4426270T3 PL 22813505 T PL22813505 T PL 22813505T PL 4426270 T3 PL4426270 T3 PL 4426270T3
Authority
PL
Poland
Prior art keywords
lipid nanoparticles
oligonucleotide delivery
oligonucleotide
delivery
nanoparticles
Prior art date
Application number
PL22813505.9T
Other languages
English (en)
Polish (pl)
Inventor
AKM Ashiqul HAQUE
Sophie VALEMBOIS
Séan MC CAFFERTY
Itishri SAHU
Christiaan Cardon
Original Assignee
Ziphius Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziphius Nv filed Critical Ziphius Nv
Publication of PL4426270T3 publication Critical patent/PL4426270T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL22813505.9T 2021-11-02 2022-11-02 Nanocząsteczki lipidowe do dostarczania oligonukleotydów PL4426270T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205904 2021-11-02
EP22179399 2022-06-16
PCT/EP2022/080581 WO2023078950A1 (en) 2021-11-02 2022-11-02 Lipid nanoparticles for oligonucleotide delivery

Publications (1)

Publication Number Publication Date
PL4426270T3 true PL4426270T3 (pl) 2025-11-24

Family

ID=84364268

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22813505.9T PL4426270T3 (pl) 2021-11-02 2022-11-02 Nanocząsteczki lipidowe do dostarczania oligonukleotydów

Country Status (14)

Country Link
US (1) US20250236599A1 (https=)
EP (2) EP4613741A3 (https=)
JP (1) JP2024540108A (https=)
KR (1) KR20240099377A (https=)
AU (1) AU2022381463A1 (https=)
CA (1) CA3236653A1 (https=)
DK (1) DK4426270T3 (https=)
ES (1) ES3042660T3 (https=)
FI (1) FI4426270T3 (https=)
IL (1) IL312432B1 (https=)
MX (1) MX2024005109A (https=)
PL (1) PL4426270T3 (https=)
WO (1) WO2023078950A1 (https=)
ZA (1) ZA202403360B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN118125994A (zh) * 2022-11-25 2024-06-04 艾斯拓康医药科技(北京)有限公司 可离子化脂质及其应用
WO2024136309A1 (en) * 2022-12-23 2024-06-27 Green Cross Corporation Ionizable lipid and use thereof
CN116514696B (zh) * 2023-06-29 2023-12-01 艾斯拓康医药科技(北京)有限公司 可离子化脂质及其应用
WO2025088152A1 (en) 2023-10-27 2025-05-01 Ziphius Nv MODIFIED 5'UTRs
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025104023A1 (en) 2023-11-13 2025-05-22 Ziphius Nv MODIFIED ALPHAVIRAL nsP3
WO2025128696A1 (en) * 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025255534A1 (en) * 2024-06-07 2025-12-11 Innovac Therapeutics Hk Limited Diol-based novel ionizable lipids and their uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CN1989250B (zh) 2004-05-18 2013-11-20 阿尔法瓦克斯公司 Tc-83衍生的甲病毒属载体、颗粒和方法
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2018232120A1 (en) * 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents

Also Published As

Publication number Publication date
EP4613741A2 (en) 2025-09-10
EP4426270B1 (en) 2025-07-23
US20250236599A1 (en) 2025-07-24
IL312432B1 (en) 2026-01-01
EP4426270A1 (en) 2024-09-11
JP2024540108A (ja) 2024-10-31
MX2024005109A (es) 2024-05-31
KR20240099377A (ko) 2024-06-28
WO2023078950A1 (en) 2023-05-11
IL312432A (en) 2024-06-01
ES3042660T3 (en) 2025-11-24
FI4426270T3 (fi) 2025-09-12
DK4426270T3 (da) 2025-09-22
AU2022381463A1 (en) 2024-05-16
EP4613741A3 (en) 2025-11-12
ZA202403360B (en) 2025-08-27
CA3236653A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
IL312432A (en) Lipid nanoparticles for delivery of oligonucleotides
PL4426269T3 (pl) Nanocząstki lipidowe do dostarczania oligonukleotydów
GB2600859B (en) Improved lipid nanoparticles for delivery of nucleic acids
IL290592A (en) A cationic lipid that can be ionized for the administration of RNA
EP2792367A4 (en) LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS
IL299787A (en) Cationic lipids for use in lipid nanoparticles
EP4346781A4 (en) DNA VECTOR DELIVERY USING LIPID NANOPARTICLES
IL304759A (en) Lipids suitable for the transfer of nucleic acids
AU2016202433A1 (en) Novel low molecular weight cationic lipids for oligonucleotide delivery
IL245638B (en) A cationic lipid that undergoes ionization for DNA delivery
IL252291B (en) A cationic lipid that undergoes ionization to provide RNA
EP3399038A3 (en) Oligonucleotide analogues targeting human lmna
ES3063637T3 (en) Lipid nanoparticle compositions and methods for mrna delivery
EP2694130A4 (en) VARIABLE LENGTH CATHETER FOR DRUG DELIVERY
EP2364085A4 (en) CATIONIC RELEASABLE LIPIDS FOR NUCLEIC ACID DELIVERY SYSTEMS
EP2885045A4 (en) METHOD FOR MANUFACTURING DRUG DELIVERY FORMULATIONS
CA3266203A1 (en) LIPID NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES
IL246378A0 (en) A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer
EP2670780A1 (en) Cellulose-based nanoparticles for drug delivery
PT4426270T (pt) Nanopartículas lipídicas para distribuição de oligonucleótidos
GB201110632D0 (en) Drug delivery formulations
ZA202301633B (en) Solid lipid nanoparticles for targetted drug delivery
GB202316478D0 (en) Lipid nanoparticles
GB202411975D0 (en) Nanoparticles for extended release drug delivery